# Donanemab therapy in Alzheimer’s disease with mild cognitive impairment: Convergent amyloid, tau, and plasma biomarker normalization with cognitive improvement

**Authors:** Limoran Tang, Yun Xu, Hui Zhao

PMC · DOI: 10.1016/j.tjpad.2026.100533 · 2026-03-14

## Full-text entities

- **Genes:** APOE (apolipoprotein E) [NCBI Gene 348] {aka AD2, APO-E, ApoE4, LDLCQ5, LPG}, MAPT (microtubule associated protein tau) [NCBI Gene 4137] {aka DDPAC, FTD1, FTDP-17, MAPTL, MSTD, MTBT1}, APP (amyloid beta precursor protein) [NCBI Gene 351] {aka AAA, ABETA, ABPP, AD1, APPI, CTFgamma}
- **Diseases:** hyperlipidemia (MESH:D006949), Dementia (MESH:D003704), hypertension (MESH:D006973), amyloid (MESH:C000718787), AD (MESH:D000544), memory impairment (MESH:D008569), stroke (MESH:D020521), MCI (MESH:D060825), C (OMIM:211750), white-matter hyperintensities (MESH:D056784), atrophy (MESH:D001284), ARIA (MESH:C564543), AUR (MESH:D019966), cognitive impairment (MESH:D003072)
- **Chemicals:** 18F- (MESH:C000615276), 18F-Florzolotau (-), 18F-Florbetapir (MESH:C545186)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12999294/full.md

---
Source: https://tomesphere.com/paper/PMC12999294